Get to know our clinical trials
Clinical trial to investigate safety and tolerability of TransCon IL-2 in adult participants with malignant solid tumors
THE OBJECTIVE OF THIS RESEARCH IS TO LEARN ABOUT THE EFFECTS OF AN EXPERIMENTAL DRUG CALLED TRANSCON IL-2 SS/? WHEN ADMINISTERED ALONE OR IN COMBINATION WITH PEMBROLIZUMAB, CHEMOTHERAPY ET OR TRANSCON TLR7/8 AGONIST, OR IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY ET.
Technical Summary
- PHASE I/II, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF TRANSCON IL-2 SS/? ALONE OR IN COMBINATION WITH PEMBROLIZUMAB, STANDARD CHEMOTHERAPY OR TRANSCON TLR7/8 AGONIST, OR IN COMBINATION WITH PEMBROLIZUMAB AND STANDARD CHEMOTHERAPY, IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC MALIGNANT SOLID TUMORS
- Code EudraCT: 2022-001191-34
- Protocol number: ASND0029
- Promoter: Ascendis Pharma Oncology Division S/A
- Molecule/Drug: TransCon IL-2
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.